Monthly semaglutide sales rose roughly 175% from March to September as cheaper brands spread, while doctors say the early rush is fading.
Recap by typeshit. Full story at Business Standard.
The Medicare GLP-1 Bridge pilot runs July 2026 through 2027, covering FDA-approved pills and shots with no deductible for eligible Part D enrollees.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
He says the peptide has almost no human data and is only sold online as a research chemical, so both the compound and its sourcing carry unknown risks.
Biomea Fusion was set to release early results for its investigational obesity candidate on October 13, with shares at $1.44 in premarket trading.
Loading…